vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Massimo Group (MAMO). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $21.0M, roughly 1.8× Massimo Group). Massimo Group runs the higher net margin — 9.5% vs -161.8%, a 171.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 15.7%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Massimo Dutti, S.A. is a Spanish premium clothing retailer specializing in cashmere and wool products, established in 1985 and owned by Spanish multinational company Inditex, the parent company of Zara, Pull&Bear, and other brands.
IBRX vs MAMO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $21.0M |
| Net Profit | $-61.9M | $2.0M |
| Gross Margin | 99.0% | 41.5% |
| Operating Margin | -169.0% | 13.1% |
| Net Margin | -161.8% | 9.5% |
| Revenue YoY | 407.0% | 15.7% |
| Net Profit YoY | -4.7% | 215.0% |
| EPS (diluted) | $-0.06 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $21.0M | ||
| Q3 25 | $32.1M | $17.0M | ||
| Q2 25 | $26.4M | $18.9M | ||
| Q1 25 | $16.5M | $14.9M | ||
| Q4 24 | $7.6M | $18.2M | ||
| Q3 24 | $6.1M | $25.6M | ||
| Q2 24 | — | $35.4M | ||
| Q1 24 | — | $30.2M |
| Q4 25 | $-61.9M | $2.0M | ||
| Q3 25 | $-67.3M | $1.5M | ||
| Q2 25 | $-92.6M | $77.7K | ||
| Q1 25 | $-129.6M | $-2.1M | ||
| Q4 24 | $-59.2M | $-1.7M | ||
| Q3 24 | $-85.7M | $-2.5M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | 99.0% | 41.5% | ||
| Q3 25 | 99.4% | 42.0% | ||
| Q2 25 | 99.5% | 36.3% | ||
| Q1 25 | 99.6% | 28.4% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 27.2% | ||
| Q2 24 | — | 32.5% | ||
| Q1 24 | — | 34.7% |
| Q4 25 | -169.0% | 13.1% | ||
| Q3 25 | -173.5% | 10.5% | ||
| Q2 25 | -269.8% | 0.8% | ||
| Q1 25 | -390.1% | -18.2% | ||
| Q4 24 | -919.0% | -15.4% | ||
| Q3 24 | -1314.3% | 1.2% | ||
| Q2 24 | — | 10.1% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | -161.8% | 9.5% | ||
| Q3 25 | -209.8% | 9.0% | ||
| Q2 25 | -350.3% | 0.4% | ||
| Q1 25 | -784.9% | -14.0% | ||
| Q4 24 | -783.4% | -9.5% | ||
| Q3 24 | -1404.0% | -9.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 10.6% |
| Q4 25 | $-0.06 | $0.05 | ||
| Q3 25 | $-0.07 | $0.04 | ||
| Q2 25 | $-0.10 | $0.00 | ||
| Q1 25 | $-0.15 | $-0.05 | ||
| Q4 24 | $-0.08 | $-0.05 | ||
| Q3 24 | $-0.14 | $-0.06 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $5.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $23.7M |
| Total Assets | $501.9M | $51.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $5.8M | ||
| Q3 25 | $257.8M | $2.6M | ||
| Q2 25 | $153.7M | — | ||
| Q1 25 | $61.6M | $3.0M | ||
| Q4 24 | $149.8M | $10.2M | ||
| Q3 24 | $130.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-500.5M | $23.7M | ||
| Q3 25 | $-524.3M | $21.7M | ||
| Q2 25 | $-570.7M | $20.2M | ||
| Q1 25 | $-591.4M | $19.9M | ||
| Q4 24 | $-489.1M | $21.7M | ||
| Q3 24 | $-745.1M | $22.5M | ||
| Q2 24 | — | $24.7M | ||
| Q1 24 | — | $18.1M |
| Q4 25 | $501.9M | $51.4M | ||
| Q3 25 | $519.0M | $44.4M | ||
| Q2 25 | $402.1M | $45.9M | ||
| Q1 25 | $303.8M | $46.4M | ||
| Q4 24 | $382.9M | $54.9M | ||
| Q3 24 | $364.6M | $57.1M | ||
| Q2 24 | — | $49.9M | ||
| Q1 24 | — | $47.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $4.0M |
| Free Cash FlowOCF − Capex | $-71.3M | — |
| FCF MarginFCF / Revenue | -186.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | 2.01× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $4.0M | ||
| Q3 25 | $-68.9M | $633.2K | ||
| Q2 25 | $-79.7M | $-1.4M | ||
| Q1 25 | $-85.9M | $-3.3M | ||
| Q4 24 | $-85.1M | $9.1M | ||
| Q3 24 | $-98.8M | $4.7M | ||
| Q2 24 | — | $-6.5M | ||
| Q1 24 | — | $-637.0K |
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | $9.0M | ||
| Q3 24 | $-101.6M | $4.6M | ||
| Q2 24 | — | $-6.7M | ||
| Q1 24 | — | $-741.4K |
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | 49.7% | ||
| Q3 24 | -1663.2% | 18.1% | ||
| Q2 24 | — | -19.0% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | 0.2% | ||
| Q3 24 | 45.7% | 0.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 2.01× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | -17.92× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.30× | ||
| Q1 24 | — | -0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
